Autologous– tag –
-
NueCell Bio Unveils 26,300 Sq Ft Cell Therapy Development Facility in San Diego, Bolstering Clinical & Commercial Manufacturing
PharmaSource USA Overview NueCell Bio has officially opened its 26,300-square-foot cell therapy development facility in San Diego, significantly enhancing its clinical and commercial manufacturing capabilities. The state-of-the-art facil... -
Chemically Defined Media and Automation Key to Overcoming Raw Material Variability in Autologous Cell Therapy Manufacturing
BioProcess International USA Overview Addressing raw material variability in autologous adoptive cell therapies necessitates the adoption of chemically defined media, standardized handling, automation, and well-characterized unit operati... -
Allogeneic Cell Therapy Manufacturing: Broad Applicability, Scalability, and Automation Driving Future Advances
Industry Informational Article USA Overview This article provides a comprehensive overview of allogeneic cell therapy manufacturing, highlighting its advantages over autologous approaches, including broader applicability, superior scalab... -
Liv Hospital Highlights Off-the-Shelf Allogeneic CAR-T Manufacturing for Enhanced Accessibility via Standardized Donor Cells
Liv Hospital Turkey Overview Liv Hospital is championing the development of allogeneic CAR-T cell manufacturing as an 'off-the-shelf' solution, leveraging standardized donor cells to significantly improve treatment accessibility. This ad... -
Off-the-Shelf Advantage: How Scalable Manufacturing Drives Clinical Success for Combination Cell Therapies
Industry Publication USA Overview A recent industry analysis underscores the critical role of manufacturability and scalability from the earliest stages of development for the clinical success of cell therapies, particularly complex comb... -
Point-of-Care Cell Therapy Manufacturing Surges Forward with Miltenyi Biotec’s CliniMACS Prodigy and Octane Medical’s Cocoon Systems
BioPharm International USA Overview Miltenyi Biotec's CliniMACS Prodigy and Octane Medical Group's Cocoon systems are emerging as pivotal technologies for accelerating point-of-care (PoC) manufacturing in cell therapy. These modular, clo... -
Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence
Catalent USA Overview Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treat... -
Sonoma Biotherapeutics Automates Autologous CAR-Treg Therapy Manufacturing for Rheumatoid Arthritis with Cellares’ Cell Shuttle Platform
Regen Report USA Overview Sonoma Biotherapeutics partnered with Cellares to automate manufacturing of its Phase 1 autologous CAR-Treg therapy (SBT-77-7101) for treatment-resistant rheumatoid arthritis, using Cellares' Cell Shuttle platfo... -
Reinventing CAR T-Cell Access: How Localized Manufacturing in Turkey and China is Driving Down Costs
Bookimed Turkey Overview The prohibitively high cost of CAR T-cell therapy severely limits patient access worldwide, with prices fluctuating significantly based on manufacturing and treatment location. However, localized production, nota... -
Allogeneic CAR-T Manufacturing: Unlocking Rapid, Off-the-Shelf Cancer Therapy
Liv Hospital Turkey Overview Allogeneic CAR-T cell manufacturing is poised to revolutionize cancer treatment by providing 'off-the-shelf' solutions derived from healthy donor cells. This approach dramatically shortens treatment timelines...
